Table 1 Characteristics of the included studies
Study | Trial Name | Country | Sample size | Mean age | Male (%) | Baseline LVEF | Injection time interval(d) | Modality | F/U for clinical events(m) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BM-MNC | Control | BM-MNC | Control | BM-MNC | Control | BM-MNC | Control | ||||||
Meyer et al. [27] | BOOST | Germany | 30 | 30 | 53.4 ± 14.8 | 59.2 ± 13.5 | 67 | 73 | 50 ± 10 | 51.3 ± 9.3 | 4.8 ± 1.3 | CMR | 61 |
Assmus et al. [12] | REAPIR-AMI | Germany | 101 | 103 | 55 ± 11 | 57 ± 11 | 82 | 82 | 47.5 ± 10 | 46.7 ± 10.3 | 4.4 ± 1.3 | LV angiography | 60 |
Beitnes et al. [32] | ASTAMI | Norway | 50 | 50 | 58.1 ± 8.5 | 56.7 ± 9.6 | 84 | 84 | 45.7 ± 9.4 | 46.9 ± 9.6 | 4–8 | Echo/CMR | 36 |
Benedek et al. [33] | - | Romania | 9 | 9 | 53.55 ± 15.08 | 61 ± 10.06 | 77.77 | 55.55 | 41.66 ± 3.5 | 39.7 ± 3 | 21–90 | Echo | 48 |
Delewi et al. [13] | HEBE | Netherlands | 69 | 65 | 56 ± 9 | 55 ± 10 | 84 | 86 | 43.7 ± 9 | 42.4 ± 8.3 | 8 | CMR | 60 |
Hu et al. [14] | CHINA-AMI | China | 22 | 14 | 60.45 ± 11.4 | 60.62 ± 10.85 | 86.5 | 64 | 53.8 ± 11.5 | 57.1 ± 11.6 | 5 | Echo/SPECT | 12 |
Huang et al. [15] | - | China | 79 | 25 | 58.55 ± 8.72 | 58.8 ± 8.4 | 91 | 88 | 43.65 ± 5.21 | 43.5 ± 3.5 | 1–30 | Echo/SPECT | 12 |
Huikuri et al. [16] | FINCELL | Finland | 40 | 40 | 60 ± 10 | 59 ± 10 | 90 | 85 | 59 ± 11 | 62 ± 12 | 2–6 | LV angiography/echo | 6 |
Lamriault et al. [17] | BONAMI | France | 59 | 42 | 56 ± 12 | 55 ± 11 | 80.8 | 89.8 | 38.1 ± 7.9 | 39.8 ± 7 | 9.3 ± 1.7 | Echo | 12 |
Mathur et al. [9] | BAMI | UK | 185 | 190 | 59 ± 11 | 60 ± 11 | 83.78 | 77.37 | 39 ± 5 | 39 ± 5 | 2–8 | Echo | 24 |
Meluzin et al. [18] | - | Czech | 40 | 20 | 54 ± 2 | 55 ± 2 | 92.5 | 90 | 40.5 ± 8.94 | 40 ± 8.94 | 3–8 | Echo/SPECT | 12 |
Plewka et al. [19] | - | Poland | 40 | 20 | 56 ± 9 | 56 ± 9 | 67 | 75 | 35 ± 6 | 33 ± 7 | 7 | Echo | 24 |
San Roman et al. [20] | TECAM | Spain | 30 | 31 | 54 ± 11 | 57 ± 11 | 97 | 90 | 49 ± 8 | 47 ± 8 | 3–5 | CMR/LV angiography | 12 |
Skalicka et al. [21] | - | Czech | 17 | 10 | 61 ± 14 | 54 ± 10 | 71 | 100 | 39.2 ± 9.2 | 39.4 ± 5.6 | 4–11 | Echo | 24 |
Sürder et al. [22] | - | Switzerland | 133 | 67 | 58.53 ± 14.77 | 56 ± 14.5 | 84 | 83.6 | 36.4 ± 8.9 | 40 ± 9.9 | 5–28 | CMR | 12 |
Traverse et al. [23] | TIME (phase I) | USA | 30 | 10 | 52.5 ± 15.56 | 57.5 ± 3.7 | 83 | 60 | 49 ± 9.5 | 48.6 ± 8.5 | 3–10 | CMR/Echo | 6 |
Traverse et al. [24] | LateTIME | USA | 58 | 29 | 57.6 ± 11 | 54.6 ± 11 | 79 | 90 | 48.7 ± 12 | 45.3 ± 9.9 | 14–21 | CMR | 6 |
Traverse et al. [25] | TIME | USA | 58 | 27 | 55.9 ± 11 | 56.4 ± 10.4 | 88 | 86 | 45.9 ± 9.4 | 46.9 ± 8.7 | 3–7 | CMR | 24 |
Wöhrle et al. [26] | - | Germany | 29 | 13 | 61 ± 8.1 | 61.1 ± 9.3 | 90 | 62 | 53.5 ± 9.3 | 55.7 ± 9.4 | 5–7 | CMR | 6 |
Piepoli et al. [28] | Cardiac study | Italy | 19 | 19 | 63.1 ± 2.4 | 67 ± 2.7 | 68.4 | 68.4 | 38.9 ± 1.3 | 38.4 ± 1.5 | 4–7 | Echo/SPECT | 12 |
Tendera et al. [29] | REGENT | Poland | 160 | 40 | 56.5 ± 29.98 | 59 ± 26.67 | 67 | 75 | 36 ± 21.2 | 39 ± 15.56 | 3–12 | CMR | 6 |
Wollert et al. [30] | BOOST-2 | Germany | 127 | 26 | 55.46 ± 9.83 | 55 ± 9 | 85 | 92 | 44.3 ± 8.48 | 47.8 ± 6.7 | 7.1 ± 2.6 | CMR | 6 |
Yao et al. [31] | - | China | 27 | 12 | 51.7 ± 6.4 | 52.7 ± 7.8 | 81 | 92 | 33.2 ± 3.9 | 32.3 ± 2 | 3d-3 m | CMR | 12 |